These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 16916081)
1. A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. Stamatakos GS; Antipas VP; Uzunoglu NK IEEE Trans Biomed Eng; 2006 Aug; 53(8):1467-77. PubMed ID: 16916081 [TBL] [Abstract][Full Text] [Related]
2. Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. Stamatakos GS; Antipas VP; Uzunoglu NK Comput Biol Med; 2006 Nov; 36(11):1216-34. PubMed ID: 16207487 [TBL] [Abstract][Full Text] [Related]
3. Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: a 4D simulation model of the tumor response. Antipas VP; Stamatakos GS; Uzunoglu NK Conf Proc IEEE Eng Med Biol Soc; 2005; 2005():6100-3. PubMed ID: 17281655 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Sipos L; Vitanovics D; Afra D Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767 [TBL] [Abstract][Full Text] [Related]
6. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Cohen MH; Johnson JR; Pazdur R Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6767-71. PubMed ID: 16203762 [TBL] [Abstract][Full Text] [Related]
7. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial. Mason WP; Cairncross JG Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504 [TBL] [Abstract][Full Text] [Related]
8. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943 [TBL] [Abstract][Full Text] [Related]
9. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. Keles GE; Lamborn KR; Chang SM; Prados MD; Berger MS J Neurosurg; 2004 Jan; 100(1):41-6. PubMed ID: 14743910 [TBL] [Abstract][Full Text] [Related]
10. Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. Teixeira MM; Garcia I; Portela I; Cernuda M; Oliveira C; Albano J; Lima L Int J Clin Pharmacol Res; 2002; 22(1):19-22. PubMed ID: 12395915 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. De Sanctis V; Mazzarella G; Osti MF; Valeriani M; Alfó M; Salvati M; Banelli E; Tombolini V; Enrici RM Anticancer Drugs; 2006 Sep; 17(8):969-75. PubMed ID: 16940807 [TBL] [Abstract][Full Text] [Related]
12. [Temozolomide in patients with a glioblastoma multiforme: new developments]. Bromberg JE; Postma TJ Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689 [TBL] [Abstract][Full Text] [Related]
13. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant temozolomide: how long and how much? Franceschi E; Tosoni A; Brandes AA Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038 [No Abstract] [Full Text] [Related]
15. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566 [TBL] [Abstract][Full Text] [Related]
16. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514 [TBL] [Abstract][Full Text] [Related]
17. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. Wick W; Weller M J Clin Oncol; 2005 Jun; 23(18):4235-6; author reply 4236. PubMed ID: 15961774 [No Abstract] [Full Text] [Related]
18. A patient-specific in vivo tumor and normal tissue model for prediction of the response to radiotherapy. Stamatakos G; Antipas VP; Ozunoglu NK Methods Inf Med; 2007; 46(3):367-75. PubMed ID: 17492124 [TBL] [Abstract][Full Text] [Related]
19. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602 [TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]